Swiss multinational healthcare holding company operating worldwide under two divisions: Pharmaceuticals and Diagnostics; the fifth-largest pharmaceutical company in the world by revenue and a leading global provider of cancer treatments.
Clinical Trials
2171
142 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1896
Not yet recruiting
23
1.1%
No Longer Available
4
0.2%
Terminated
199
9.2%
Recruiting
92
4.2%
Suspended
1
0.1%
Withdrawn
46
2.1%
Active, not recruiting
119
5.5%
Unknown
3
0.1%
Completed
1683
77.5%
No approval data available
- The oncology landscape added 278 new bi- and multispecific drugs during 2024/25, alongside more than 8,566 events across 2,120 drug programs. - Over 800 drugs were associated with new events, underscoring the accelerating pace and complexity of bi- and multispecific drug development. - A new analytical tool tracks 481 therapeutic targets, 167 tumor types, 1,481 clinical trials, and 350 deals, with Amgen, Roche/Genentech, and J&J among leading developers. - The platform leverages an AI-enhanced intelligence system with over 25 years of oncology expertise to support competitive, clinical, and business decision-making.
- Manufacturing accounts for roughly 80% of a pharmaceutical company's environmental footprint, making the factory floor the critical intervention point for meaningful change. - Eight leading APAC CDMOs are integrating renewable electricity, water reuse, waste recovery, green chemistry and continuous manufacturing into core production strategy rather than isolated initiatives. - The global sustainable drug manufacturing market is projected to grow from USD 105.8 billion in 2026 to USD 248.2 billion by 2036 at an 8.9% CAGR. - Scope 3 emissions, supplier engagement and internal carbon pricing are emerging as the next frontier, with WuXi AppTec reporting 82.14% of emissions from Scope 3.
- Azenta, Inc. has appointed Board member Dr. Martin Madaus as interim President and CEO following the resignation of John Marotta as executive officer and director. - The Board has retained Heidrick & Struggles to lead a search for a permanent CEO while reaffirming fourth quarter fiscal 2026 total revenue guidance. - Fourth quarter fiscal 2026 adjusted EBITDA will be impacted by a one-time consulting expense of approximately $3 million, excluding which the Company would reaffirm adjusted EBITDA. - Dr. Madaus brings more than 30 years of diagnostics and life science tools leadership experience, including prior CEO roles at Millipore, Ortho-Clinical Diagnostics, and Roche Diagnostics North America.
- The global non-tyrosine kinase inhibitors market is projected to grow from USD 9.4 billion in 2026 to USD 18.7 billion by 2036, at a 7.1% CAGR. - CDK inhibitors are forecast to hold 31.0% of drug-class demand in 2026, anchored by established CDK4/6 use in hormone-receptor-positive breast cancer. - Oncology is expected to account for 68.0% of application demand, with recent FDA approvals linking inavolisib to PIK3CA-mutated breast cancer and capivasertib to PTEN-deficient prostate cancer. - Oral administration holds a 74.0% share, though ECG checks, laboratory testing, and boxed safety warnings can slow routine adoption after regulatory approval.
- The Southeast Asia oncology drug access market is projected to grow from USD 3.19 billion in 2026 to USD 4.41 billion by 2031, at a CAGR of 6.7%. - Rising cancer burden, particularly breast, lung, colorectal, liver, and cervical cancers, alongside hematologic malignancies, is fueling demand for affordable oncology therapies. - Biosimilars, generics, patient assistance programs, and precision oncology advances are reshaping treatment accessibility across the region. - Key challenges include high out-of-pocket costs, fragmented regulations, and rural infrastructure limitations, though healthcare reforms present growth opportunities.
- Biocad has opened patient enrollment for a Phase III trial comparing its trastuzumab emtansine biosimilar BCD-237 against Roche's original Kadcyla in HER2-positive breast cancer. - The study will enroll 488 female patients across 48 clinical centers in Russia, with completion expected by the end of 2031. - Kadcyla remains the only trastuzumab emtansine product registered in Russia and ranked among the top five hospital procurement drugs by value in 2025. - The original Kadcyla was approved in the U.S. in 2013 as the first ADC for HER2-positive breast cancer and was registered in Russia in 2014.
- Valo Health appointed Karin Conde-Knape, Ph.D., as Chief Scientific Officer, bringing over two decades of drug development expertise from Novo Nordisk to advance AI-enabled drug discovery. - Dr. Conde-Knape previously served as Senior Vice President of Early Development and Global Drug Discovery at Novo Nordisk, leading research across multiple therapeutic areas. - The appointment follows the planned retirement of current CSO Mike Graziano, Ph.D., who will transition to a Scientific Advisor role after advancing Valo's platform and partnerships. - Dr. Conde-Knape will oversee scientific strategy and execution for Valo's diverse portfolio of internal programs and global collaborations aimed at delivering transformative therapies.
- Over 100 pharmaceutical companies are actively developing more than 100 pipeline drugs for eczema treatment, representing a significant expansion in therapeutic options for this chronic inflammatory skin condition. - Sanofi's Amlitelimab achieved all primary and key secondary endpoints in the Phase III COAST 1 study, demonstrating statistically significant skin clearance in patients with moderate-to-severe atopic dermatitis at Week 24. - The pipeline features diverse mechanisms of action including OX40 ligand inhibitors, interleukin receptor antagonists, and STAT6 transcription factor degraders, with approximately 10+ drugs in late-stage development. - Recent clinical milestones include positive Phase I results for Concerto Biosciences' ENS-002 topical biotherapeutic and FDA clearance for Sitryx Therapeutics' SYX-5219 Phase Ib trial.
- Hemlibra has shown efficacy in preventing bleeding during exercise for patients with Hemophilia A, marking a significant advancement in activity-related bleeding management. - Pfizer reported positive results from its Phase III BAISIS trial for hemophilia treatment, adding to the growing pipeline of therapeutic options. - A comprehensive global clinical trials review reveals ongoing research activity across multiple pharmaceutical companies in the Hemophilia A treatment landscape. - The clinical development efforts span major pharmaceutical companies including Roche, Pfizer, Takeda, Bayer, and Sanofi, indicating robust industry investment in hemophilia therapeutics.
- Over 20 pharmaceutical and biotech companies are actively developing more than 20 therapeutic candidates for Huntington's disease at various clinical and preclinical stages. - PTC Therapeutics received FDA Fast Track designation for PTC518 in September 2024 and signed a licensing agreement with Novartis worth up to $2.9 billion for its development. - The FDA expanded valbenazine (Ingrezza) indication in August 2023 to include Huntington's disease-associated chorea, making it the only approved selective VMAT2 inhibitor for this condition. - Key pipeline candidates include RG6042 (Hoffmann-La Roche), PTC518 (PTC Therapeutics), and ALN-HTT02 (Alnylam Pharmaceuticals), targeting different mechanisms to reduce huntingtin protein production.
